# Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

> **NCT04376684** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1156 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome

## Interventions

- **BIOLOGICAL:** Otilimab
- **BIOLOGICAL:** Placebo 1
- **BIOLOGICAL:** Placebo 2
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT04376684
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-28
- **Primary completion:** 2021-07-15
- **Final completion:** 2021-08-16
- **Target enrollment:** 1156 (ACTUAL)
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04376684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04376684, "Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04376684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*